PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Rank in Stocks #1422
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Share Price
$37.84
Market Cap
$15.65B
Change (1 day)
-4.42%
Change (1 year)
149.23%
Country
TW
Trade PharmaEssentia Corporation (6446)

Category

Healthcare
Dividend history for PharmaEssentia Corporation (6446)
PharmaEssentia Corporation (stock symbol: 6446) made a total of 1 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $0.99
Dividend yield (TTM) : 0.0012
Dividend payments for PharmaEssentia Corporation (6446) from 2025 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
2026 (TTM) $0.9898 0.00%
2025 $0.9898 0.00%
List of all dividend payments
Year Dividend Change
2026 (TTM) $1.10 0.00%
2025 $1.10 0.00%
Dividend payments for similar companies or competitors